{
    "nct_id": "NCT05797831",
    "official_title": "A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy",
    "inclusion_criteria": "* ECOG 0-1\n* Histologically or cytologically confirmed diagnosis of endometrial cancer documented as TP53WT\n* Subjects with advanced or recurrent disease must have completed a single line of up to 6 cycles of taxane-platinum based chemo and achieved a CR or PR per RECIST V1.1\n* Adequate hematologic, hepatic and renal function (within 14 days)\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has any sarcomas or small-cell carcinomas with neuroendocrine differentiation\n* Prior immune therapy, cytokine therapy, or any investigational therapy (within 28 days)\n* Indwelling surgical drains\n* Grade 2 or higher QTc prolongation\n* History of major organ transplant\n* History of bleeding diathesis; major hemorrhage or intracranial hemorrhage (within 24 weeks)",
    "miscellaneous_criteria": ""
}